Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain

EU orphan designation number: EU/3/14/1396   
Active ingredient: Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain
Indication: Treatment of glioma
Sponsor: Boyd Consultants Limited
Dublin City University, DCU Invent, Glasnevin, Dublin 9, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/12/2014 Orphan designation EMA/OD/176/14 (2014)10044 of 16/12/2014
15/03/2019 Transfer of orphan designation EMA/OD/0000005074 (2019)2109 of 13/03/2019